Brief: PDS Biotech Completes Successful Meeting With FDA For Triple Combination Of Pds0101, Pds0301 And A Commercial Immune Checkpoint Inhibitor
27/02/2023 13:46
Feb 27 (Reuters) - PDS Biotechnology Corp PDSB.O :
* PDS BIOTECH COMPLETES SUCCESSFUL MEETING WITH FDA FOR
TRIPLE
COMBINATION OF PDS0101, PDS0301 AND A COMMERCIAL IMMUNE
CHECKPOINT INHIBITOR
Source text for Eikon: ID:nGNX4xLgpw
Further company coverage: PDSB.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on PDS Biotechnology
See all newsPDS Biotechnology Corp reports results for the quarter ended September 30 - Earnings Summary
PDS Biotechnology Q3 net loss narrows on lower R&D costs
PDS Biotechnology Corp expected to post a loss of 10 cents a share - Earnings Preview
Brief: PDS Biotech Announces Initial Closing Of Up To $22.3 Mln PIPE Financing
Brief: Pds Biotechnology Corp - On Aug 6, Approved Reduction In Force To Align Expenses With Strategic Priorities - SEC Filing